319 631

Cited 19 times in

A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea.

DC Field Value Language
dc.contributor.author박승우-
dc.contributor.author방승민-
dc.contributor.author송시영-
dc.contributor.author이희승-
dc.contributor.author정문재-
dc.contributor.author박정엽-
dc.date.accessioned2017-11-02T08:11:35Z-
dc.date.available2017-11-02T08:11:35Z-
dc.date.issued2017-
dc.identifier.issn0025-7974-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/154182-
dc.description.abstractBACKGROUND: This phase III trial compared the efficacy and safety of gemcitabine plus capecitabine (GemCap) versus single-agent gemcitabine (Gem) in advanced pancreatic cancer as first-line chemotherapy. METHODS: A total of 214 advanced pancreatic cancer patients were enrolled from 16 hospitals in South Korea between 2007 and 2011. Patients were randomly assigned to receive GemCap (oral capecitabine 1660 mg/m plus Gem 1000 mg/m by 30-minute intravenous infusion weekly for 3 weeks followed by a 1-week break every 4 weeks) or Gem (by 30-minute intravenous infusion weekly for 3 weeks every 4 weeks). RESULTS: Median overall survival (OS) time, the primary end point, was 10.3 and 7.5 months in the GemCap and Gem arms, respectively (P = 0.06). Progression-free survival was 6.2 and 5.3 months in the GemCap and Gem arms, respectively (P = 0.08). GemCap significantly improved overall response rate compared with Gem alone (43.7% vs 17.6%; P = 0.001). Overall frequency of grade 3 or 4 toxicities was similar in each group. Neutropenia was the most frequent grade 3 or 4 toxicity in both groups. CONCLUSION: GemCap failed to improve OS at a statistically significant level compared to Gem treatment. This study showed a trend toward improved OS compared to Gem alone. GemCap and Gem both exhibited similar safety profiles.-
dc.description.statementOfResponsibilityopen-
dc.formatapplication/pdf-
dc.languageEnglish-
dc.publisherLippincott Williams & Wilkins-
dc.relation.isPartOfMEDICINE-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdenocarcinoma/drug therapy*-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAged, 80 and over-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/adverse effects-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/therapeutic use*-
dc.subject.MESHCapecitabine/administration & dosage-
dc.subject.MESHDeoxycytidine/administration & dosage-
dc.subject.MESHDeoxycytidine/adverse effects-
dc.subject.MESHDeoxycytidine/analogs & derivatives*-
dc.subject.MESHDeoxycytidine/therapeutic use-
dc.subject.MESHDisease-Free Survival-
dc.subject.MESHFemale Humans-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeutropenia/chemically induced-
dc.subject.MESHPancreatic Neoplasms/drug therapy*-
dc.subject.MESHRepublic of Korea-
dc.subject.MESHResponse Evaluation Criteria in Solid Tumors-
dc.subject.MESHSurvival Rate-
dc.titleA randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea.-
dc.typeArticle-
dc.publisher.locationUnited States-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Internal Medicine-
dc.contributor.googleauthorHee Seung Lee-
dc.contributor.googleauthorMoon Jae Chung-
dc.contributor.googleauthorJeong Youp Park-
dc.contributor.googleauthorSeungmin Bang-
dc.contributor.googleauthorSeung Woo Park-
dc.contributor.googleauthorHo Gak Kim-
dc.contributor.googleauthorMyung Hwan Noh-
dc.contributor.googleauthorSang Hyub Lee-
dc.contributor.googleauthorYong-Tae Kim-
dc.contributor.googleauthorHyo Jung Kim-
dc.contributor.googleauthorChang Duck Kim-
dc.contributor.googleauthorDong Ki Lee-
dc.contributor.googleauthorKwang Bum Cho-
dc.contributor.googleauthorChang Min Cho-
dc.contributor.googleauthorJong Ho Moon-
dc.contributor.googleauthorDong Uk Kim-
dc.contributor.googleauthorDae Hwan Kang-
dc.contributor.googleauthorYoung Koog Cheon-
dc.contributor.googleauthorHo Soon Choi-
dc.contributor.googleauthorTae Hyeon Kim-
dc.contributor.googleauthorJae Kwang Kim-
dc.contributor.googleauthorJieun Moon-
dc.contributor.googleauthorHye Jung Shin-
dc.contributor.googleauthorSi Young Song-
dc.identifier.doi10.1097/MD.0000000000005702-
dc.contributor.localIdA01786-
dc.contributor.localIdA02035-
dc.contributor.localIdA03349-
dc.contributor.localIdA03602-
dc.contributor.localIdA01647-
dc.contributor.localIdA01551-
dc.relation.journalcodeJ02214-
dc.identifier.eissn1536-5964-
dc.identifier.pmid28072706-
dc.contributor.alternativeNamePark, Seung Woo-
dc.contributor.alternativeNameBang, Seung Min-
dc.contributor.alternativeNameSong, Si Young-
dc.contributor.alternativeNameLee, Hee Seung-
dc.contributor.alternativeNameChung, Moon Jae-
dc.contributor.alternativeNamePark, Jeong Youp-
dc.contributor.affiliatedAuthorBang, Seung Min-
dc.contributor.affiliatedAuthorSong, Si Young-
dc.contributor.affiliatedAuthorLee, Hee Seung-
dc.contributor.affiliatedAuthorChung, Moon Jae-
dc.contributor.affiliatedAuthorPark, Jeong Youp-
dc.contributor.affiliatedAuthorPark, Seung Woo-
dc.citation.titleMedicine-
dc.citation.volume96-
dc.citation.number1-
dc.citation.startPage5702-
dc.identifier.bibliographicCitationMEDICINE, Vol.96(1) : 5702, 2017-
dc.date.modified2017-11-01-
dc.identifier.rimsid42146-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.